Information blocking fines are now fair game in health care

LIONELBONAVENTURE/AFPviaGettyImagesYou’rereadingthewebeditionofSTATHealthTech,ourguidetohowtechistra Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor




hotspot

author：fashion    Page View：49892
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Listen: Racing for gene therapy & a pioneering approval
Next article： 23andMe had bad news about my health. I wish a person had delivered it